AtriCure (NASDAQ:ATRC) had its price target lifted by Canaccord Genuity from $37.00 to $40.00 in a research note published on Tuesday, The Fly reports. Canaccord Genuity currently has a buy rating on the medical device company’s stock.

Other analysts also recently issued research reports about the stock. Stifel Nicolaus raised their price target on shares of AtriCure from $23.00 to $32.00 and gave the stock a buy rating in a research report on Wednesday, June 27th. Needham & Company LLC raised their price target on shares of AtriCure from $26.00 to $32.00 and gave the stock a buy rating in a research report on Monday, June 18th. BTIG Research reissued a hold rating on shares of AtriCure in a research report on Thursday, August 2nd. Zacks Investment Research raised shares of AtriCure from a sell rating to a hold rating in a research report on Friday, August 24th. Finally, Piper Jaffray Companies raised their price target on shares of AtriCure to $30.00 and gave the stock an overweight rating in a research report on Tuesday, June 26th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. AtriCure has a consensus rating of Buy and an average price target of $33.60.

Shares of NASDAQ:ATRC opened at $31.11 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.37. AtriCure has a 52-week low of $14.88 and a 52-week high of $36.49. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -39.10 and a beta of 0.17.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. AtriCure had a negative net margin of 10.85% and a negative return on equity of 16.57%. The business had revenue of $51.80 million during the quarter, compared to the consensus estimate of $49.94 million. During the same quarter last year, the company earned ($0.21) earnings per share. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, analysts anticipate that AtriCure will post -0.89 EPS for the current fiscal year.

In other news, SVP Justin J. Noznesky sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $30.32, for a total transaction of $121,280.00. Following the completion of the sale, the senior vice president now owns 124,920 shares of the company’s stock, valued at $3,787,574.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 8.70% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its stake in AtriCure by 1.4% during the second quarter. FMR LLC now owns 5,255,607 shares of the medical device company’s stock worth $142,164,000 after purchasing an additional 71,961 shares during the last quarter. BlackRock Inc. lifted its stake in AtriCure by 6.3% during the second quarter. BlackRock Inc. now owns 2,786,192 shares of the medical device company’s stock worth $75,366,000 after purchasing an additional 164,615 shares during the last quarter. Hudson Executive Capital LP lifted its stake in AtriCure by 18.4% during the first quarter. Hudson Executive Capital LP now owns 2,374,119 shares of the medical device company’s stock worth $48,717,000 after purchasing an additional 368,509 shares during the last quarter. First Light Asset Management LLC lifted its stake in AtriCure by 18.2% during the second quarter. First Light Asset Management LLC now owns 1,380,405 shares of the medical device company’s stock worth $37,340,000 after purchasing an additional 212,733 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in AtriCure by 13.6% during the first quarter. Millennium Management LLC now owns 859,871 shares of the medical device company’s stock worth $17,645,000 after purchasing an additional 102,911 shares during the last quarter. Hedge funds and other institutional investors own 90.77% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Read More: Book Value Of Equity Per Share – BVPS Explained

The Fly

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.